AIMS: The population pharmacokinetics of 131I-mAbF19, a radiolabelled murine monoclonal antibody against fibroblast activation protein and a potential antitumour stroma agent, were investigated during two phase I studies in cancer patients. METHODS: 131I-mAbF19 serum concentration-time data were obtained in 16 patients from two studies involving imaging and dosimetry in colorectal carcinoma and soft tissue sarcoma. Doses of 0.2, 1 and 2 mg antibody were administered as 60 min intravenous infusions. The data were analysed by nonlinear mixed effect modelling. RESULTS: The data were described by a two-compartment model. Population mean values were 109 ml h(-1) for total serum clearance, 3.1 l for the volume of distribution of the central compartment, and 4.9 l for the volume of distribution at steady state. Mean terminal half-life was 38 h. Intersubject variability was high, but no patient covariates could be identified that further explained this variability. In particular, there was no influence of tumour type or mAbF19 dose. CONCLUSIONS: The pharmacokinetics of antistromal mAbF19 were well defined in these two studies with different solid tumour types, and were comparable with those of other murine monoclonal antibodies that do not bind to normal tissue antigens or blood cells.
AIMS: The population pharmacokinetics of 131I-mAbF19, a radiolabelled murine monoclonal antibody against fibroblast activation protein and a potential antitumour stroma agent, were investigated during two phase I studies in cancerpatients. METHODS: 131I-mAbF19 serum concentration-time data were obtained in 16 patients from two studies involving imaging and dosimetry in colorectal carcinoma and soft tissue sarcoma. Doses of 0.2, 1 and 2 mg antibody were administered as 60 min intravenous infusions. The data were analysed by nonlinear mixed effect modelling. RESULTS: The data were described by a two-compartment model. Population mean values were 109 ml h(-1) for total serum clearance, 3.1 l for the volume of distribution of the central compartment, and 4.9 l for the volume of distribution at steady state. Mean terminal half-life was 38 h. Intersubject variability was high, but no patient covariates could be identified that further explained this variability. In particular, there was no influence of tumour type or mAbF19 dose. CONCLUSIONS: The pharmacokinetics of antistromal mAbF19 were well defined in these two studies with different solid tumour types, and were comparable with those of other murine monoclonal antibodies that do not bind to normal tissue antigens or blood cells.
Authors: S Welt; C R Divgi; F X Real; S D Yeh; P Garin-Chesa; C L Finstad; J Sakamoto; A Cohen; E R Sigurdson; N Kemeny Journal: J Clin Oncol Date: 1990-11 Impact factor: 44.544
Authors: S Welt; C R Divgi; A M Scott; P Garin-Chesa; R D Finn; M Graham; E A Carswell; A Cohen; S M Larson; L J Old Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544
Authors: E Oosterwijk; N H Bander; C R Divgi; S Welt; J C Wakka; R D Finn; E A Carswell; S M Larson; S O Warnaar; G J Fleuren Journal: J Clin Oncol Date: 1993-04 Impact factor: 44.544
Authors: W J Rettig; P Garin-Chesa; H R Beresford; H F Oettgen; M R Melamed; L J Old Journal: Proc Natl Acad Sci U S A Date: 1988-05 Impact factor: 11.205
Authors: Ron J Keizer; Miren K Zamacona; Mendel Jansen; David Critchley; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Invest New Drugs Date: 2008-08-20 Impact factor: 3.850
Authors: C Kloft; E-U Graefe; P Tanswell; A M Scott; R Hofheinz; A Amelsberg; M O Karlsson Journal: Invest New Drugs Date: 2004-01 Impact factor: 3.850